Risk-based guidelines: Redefining management of abnormal cervical cancer screening results

Amy Wiser, Jeffrey D. Quinlan, Pelin Batur

Research output: Contribution to journalArticlepeer-review

Abstract

In making the 2019 guidelines for risk-based management of patients with abnormal cervical cancer screening tests and cancer precursors, the guidelines committee shifted from results-based to risk-based management recommendations, based on the patient's immediate and 5-year risks of grade 3 or higher cervical intraepithelial neoplasia (CIN 3+). The risk is determined by current and prior screening results (human papillomavirus infection, cytology testing) and the clinical history including age. An immediate 4% or higher risk of CIN 3+ was established as the dividing line between higher and lower risks, and the corresponding management recommendations. This article reviews the changes and their evidence base and discusses clinical implications of the revised guidelines.

Original languageEnglish (US)
Pages (from-to)556-560
Number of pages5
JournalCleveland Clinic journal of medicine
Volume88
Issue number10
DOIs
StatePublished - 2021

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Risk-based guidelines: Redefining management of abnormal cervical cancer screening results'. Together they form a unique fingerprint.

Cite this